0000000000975853

AUTHOR

Rita Ferla

showing 19 related works from this author

Leptin and Its Receptor are Overexpressed in Brain Tumors and Correlate with the Degree of Malignancy

2009

Although leptin and its receptor (ObR) have emerged as important cancer biomarkers, the role of the leptin system in brain tumor development remains unknown. We screened 87 human brain tumor biopsies using immunohistochemistry and detected leptin and ObR in 55.2% and 60.9% cases, respectively. In contrast, leptin and ObR were absent in 14 samples of normal brain tissue. The presence of leptin correlated with ObR with overall concordance 80.5%. The leptin/ObR system was highly expressed in glioblastomas and anaplastic astrocytomas, while lower expression of both markers was noted in low-grade astrocytomas and gangliogliomas. The association between leptin/ObR and the degree of tumor malignan…

STAT3 Transcription Factornovel biomarkermedicine.medical_specialtyBlotting WesternBrain tumorFluorescent Antibody TechniqueCell CountBiologyleptinArticlePathology and Forensic MedicineCell Line TumorInternal medicinemedicineHumansleptin receptorProtein kinase BCell ProliferationLeptin receptorBrain NeoplasmsGeneral NeuroscienceLeptindigestive oral and skin physiologyglioblastomaBrainGliomamalignant progressionCell cyclemedicine.diseaseImmunohistochemistryOncogene Protein v-aktglioblastoma; leptin; leptin receptor; malignant progression; novel biomarkerKi-67 AntigenEndocrinologyTumor progressionReceptors LeptinImmunohistochemistryCancer biomarkersNeurology (clinical)hormones hormone substitutes and hormone antagonistsSignal TransductionBrain Pathology
researchProduct

Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.

2009

Both leptin and vascular endothelial growth factor (VEGF) are growth and angiogenic cytokines that are upregulated in different types of cancer and have been implicated in neoplastic progression. Here we investigated the molecular mechanism by which leptin and VEGF expression are regulated in colon cancer by epidermal growth factor (EGF). In colon cancer cell line HT-29, EGF induced the binding of signal transducer and activator transcription 3 (STAT3) to STAT3 consensus motifs within the VEGF and leptin promoters and stimulated leptin and VEGF mRNA and protein synthesis. All these EGF effects were significantly blocked when HT-29 cells were treated with an inhibitor of the phosphoinositide…

LeptinSTAT3 Transcription FactorVascular Endothelial Growth Factor ASmall interfering RNAPhysiologyColorectal cancerClinical BiochemistryNeovascularization PhysiologicEGF/PI3K/STAT3colorectal cancerchemistry.chemical_compoundPhosphatidylinositol 3-KinasesEpidermal growth factormedicineHumansLY294002Gene SilencingRNA MessengerSTAT3Promoter Regions GeneticPI3K/AKT/mTOR pathwayCell NucleusbiologyEpidermal Growth FactorChemistryLeptinangiogenic regulators VEGF leptinCell Biologymedicine.diseaseUp-RegulationVascular endothelial growth factorGene Expression Regulation NeoplasticCancer researchbiology.proteinColorectal NeoplasmsHT29 Cellshormones hormone substitutes and hormone antagonistsProtein Binding
researchProduct

Founder mutations in BRCA1 and BRCA2 genes

2007

BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary breast and/or ovarian cancers. The proportion of high-risk families with breast and/or ovarian cancer cases due to mutations in these tumor suppressor genes varies widely among populations. In some population, a wide spectrum of different mutations in both genes are present, whereas in other groups specific mutations in BRCA1 and BRCA2 have been reported with high frequency. Most of these mutations are prevalent in restricted populations as consequence of a founder effect. The comparison of haplotypes between families with the same mutation can distinguish whether high-frequency alleles derive f…

Genetic counselingPopulationBiologymedicine.disease_causeGermline mutationEthnicitymedicineHumansGenetic TestingeducationGenetic testingBRCA2 ProteinGeneticseducation.field_of_studyMutationmedicine.diagnostic_testBRCA1 ProteinHaplotypeHematologyPenetranceFounder EffectOncologyMutationApoptosis Regulatory ProteinsBRCA1 BRCA2 founder mutationFounder effect
researchProduct

miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.

2010

MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of different genes, including genes involved in cancer progression. A functional link between hypoxia, a key feature of the tumor microenvironment, and miRNA expression has been documented. We investigated whether and how miR-20b can regulate the expression of vascular endothelial growth factor (VEGF) in MCF-7 breast cancer cells under normoxic and hypoxia-mimicking conditions (CoCl(2) exposure). Using immunoblotting, ELISA, and quantitative real-time PCR, we demonstrated that miR-20b decreased VEGF protein levels at 4 and 24 h following CoCl(2) treatment, and VEGF mRNA at 4 h of treatment. In addition, miR-20b reduce…

STAT3 Transcription FactorVascular Endothelial Growth Factor ATime FactorsPhysiologySettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationBreast NeoplasmsBiologyTransfectionchemistry.chemical_compoundmir20b VEGFCell Line TumormicroRNAHumansSTAT3Promoter Regions GeneticG alpha subunitRegulation of gene expressionTumor microenvironmentBinding SitesCell BiologyTransfectionCobaltHypoxia-Inducible Factor 1 alpha SubunitMolecular biologyCell HypoxiaVascular endothelial growth factorGene Expression Regulation NeoplasticMicroRNAsHIF1Achemistrybiology.proteinFemaleRNA InterferenceSignal TransductionJournal of cellular physiology
researchProduct

BRCA1/2 variants of uncertain clinical significance in patients with famlial and hereditary breast/ovarian cancer

2007

researchProduct

Analysis of TP53, Ki-Ras and P16INK4A promoter methylation as potential prognostic factors in patients with colorectal cancer

2007

AnalysisTP53 Ki-Ras P16INK4A colorectal cancer
researchProduct

Acute loss of pRB function induces centrosome amplification and aneuploidy in human fibroblasts

2006

researchProduct

GENOTYPE ANALYSIS OF COLORECTAL CARCINOMAS THROUGH LASER PRESSURE CATAPULTING (LPC)

2007

n
researchProduct

BRCA 1/2 GENES MUTATIONAL SCREENING IN SICILIAN BREAST AND/OR OVARIAN CANCER FAMILIES

2007

researchProduct

BRCA 1/2 VARIANTS OF UNCERTAIN CLINICAL SIGNIFICANCE IN PATIENTS WITH FAMILIAL AND HEREDITARY BREAST/OVARIAN CANCER

2007

researchProduct

Acute loss of pRB function induces centrosome amplification and aneuploidy both in murine and human fibroblasts

2006

researchProduct

Aplotype analysis in four sicilian families with 5083del19bp-BRCA1.

2007

aplotype analysis
researchProduct

Carcinoma ereditario dell'ovaio (Ereditary Ovarian Cancer)

2007

researchProduct

Molecular analysis of TP53, Ki-Ras and P16 methylation status in tissue and plasma of subjects affected by gastrointestinal cancer

2007

researchProduct

BRCA1/BRCA2 genes mutational screening in Sicilian breast and/or ovarian cancer families.

2007

hereditary breast/ovarian cancer
researchProduct

Genotype analysis of colorectal carcinomas through laser pressare catapulting (LPC)

2007

Recently, new chemotherapy agents which target the non-structural components of mitosis have been developed. An important protein involved in several mitotic phases is the Aurora-A protein. By means of the phosphorylation of different substrates, Aurora-A regulates the correct development of the various phases of mitosis. The kinase activity of this protein makes Aurora-A an excellent candidate as an oncogene. The first data of Aurora-A involvement in cancer regarded the identification of Aurora-A overexpression in primary breast and colon tumour samples. With regard to the predictive role of Aurora-A, it has been shown that its overexpression disrupts the spindle checkpoint activated by pa…

Kinase inhibitorCancer treatmentMitosiAurora-ASmall molecule
researchProduct

Molecular analysis of TP53, Ki-Ras and P16 methylation status in tissue and plasma of subjects affected by gastrointestinal cancer (GIC)

2007

BACKGROUND: Despite the improvement in detection and surgical therapy in the last years, the outcome of patients affected by colorectal carcinoma (CRC) remains limited by metastatic relapse. The aim of this study was to investigate the presence of free tumor DNA in the plasma of CRC patients in order to understand its possible prognostic role. PATIENTS AND METHODS: Ki-Ras, TP53 mutations and p16(INK4A) methylation status were prospectively evaluated in tumor tissues and plasma of 66 CRC patients. RESULTS: In 50 of the 66 primitive tumor cases (76%) at least one significant alteration was identified in Ki-Ras and/or TP53 and/or p16(INK4A) genes. Eighteen of the 50 patients presented the same…

Settore MED/06 - Oncologia MedicaSettore MED/08 - Anatomia PatologicaMolecular analysis TP53 GIC
researchProduct

Expression level of the mammaglobin (MGB1) gene in BC:possibile index of BC progression

2007

researchProduct

TP53, Ki-Ras and P16INK4A gene molecular analysis in salivary gland tumors.

2007

n
researchProduct